PRODUCTOS ROCHE S.A.Q. e I.

Alkem Laboratories has launched Pertuza injection 420mg/14mL, an indigenously developed pertuzumab biosimilar for HER2-positive breast cancer treatment in India.

PHASE Scientific has launched the world's largest clinical study for urine-based cervical cancer screening, enrolling 17,000 women in China to evaluate their proprietary PHASiFY™ technology.

Roche announced a definitive merger agreement to acquire 89bio for $14.50 per share in cash plus contingent value rights, totaling up to $3.5 billion.

Ollin Biosciences launched with $100 million in Series A funding led by ARCH Venture Partners, Mubadala Capital, and Monograph Capital to develop next-generation ophthalmology treatments.

Roche announced the integration of its Accu-Chek SmartGuide continuous glucose monitoring solution with the mySugr diabetes management app, providing AI-enabled predictive capabilities for diabetes patients.

Dualitas Therapeutics launched from stealth with $65 million Series A funding co-led by Versant Ventures and Qiming Venture Partners USA, with participation from Eli Lilly and Company and other strategic investors.

CatalYm appointed four experienced executives to accelerate visugromab's progression into late-stage clinical development following promising Phase 2a results.

The Federal Court of Australia denied Regeneron and Bayer's preliminary injunction application against Sandoz's aflibercept biosimilars, allowing the launch of Afqlir and Enzeevu to proceed as planned.

Immix Biopharma received strategic investment from Goose Capital, led by former Tanox CEO Dr. Nancy T. Chang, who previously developed FDA-approved drugs generating over $5 billion in sales.

Foresight Diagnostics and Roche have entered a limited licensing agreement for PhasED-Seq technology, resolving litigation between the parties with all claims dismissed with prejudice.